Edgewise Therapeutics, Inc., (NASDAQ:EWTX) on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pressure tracings made from the body of the left ventricle (LV) (A), the body and left ventricular outflow tract (LVOT) (B), and LV body and aorta (C). In B, both catheters record an LV pressure ...
A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding study, 10 weeks of ...
A statistically significant reduction from baseline in Valsalva LVOT gradient was observed with mavacamten vs placebo at week 28. Topline data were announced from a phase 3 trial evaluating mavacamten ...
Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results